TW-37 is an inhibitor of the Bcl-2 family proteins Bcl-2, Mcl-1, and Bcl-xL (Kis = 120, 260, and 1,100 nM, respectively). It induces apoptosis, inhibits migration and capillary sprouting, and blocks the expression of the angiogenic chemokines CXCL1 and CXCL8 in endothelial cells. TW-37 decreases the density of functional human microvessels in the severe combined immunodeficient mouse model of human angiogenesis when administered intravenously. It has apoptotic action against leukemia, lymphoma, and pancreatic cancer cells.
TW-37 is a Bcl-2 inhibitor that suppresses growth and enhance cisplatin-induced apoptosis in ovarian cancer cells. Also functions as an MCL-1 inhibitor that kills many more malignant cells.
TW-37 is a novel nonpeptide inhibitor to recombinant Bcl-2, Bcl-xL and Mcl-1 with Ki of 0.29 μM, 1.11 μM and 0.26 μM, respectively.
ChEBI: N-[4-(2-tert-butylphenyl)sulfonylphenyl]-2,3,4-trihydroxy-5-[(2-propan-2-ylphenyl)methyl]benzamide is a member of benzamides.
